⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for childhood chronic myelogenous leukemia

Every month we try and update this database with for childhood chronic myelogenous leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic MalignanciesNCT01175785
Accelerated Pha...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Childhood Acute...
Childhood Acute...
Childhood Chron...
Childhood Myelo...
Chronic Phase C...
de Novo Myelody...
Previously Trea...
Refractory Anem...
Refractory Anem...
Refractory Anem...
Relapsing Chron...
Secondary Myelo...
umbilical cord ...
fludarabine pho...
cyclophosphamid...
ex vivo-expande...
total-body irra...
cyclosporine
mycophenolate m...
laboratory biom...
6 Months - 45 YearsNohla Therapeutics, Inc.
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell TransplantationNCT00052520
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
B-cell Adult Ac...
B-cell Childhoo...
Childhood Chron...
Childhood Myelo...
Chronic Myelomo...
Essential Throm...
Polycythemia Ve...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Refractory Anem...
Refractory Anem...
Relapsing Chron...
Secondary Acute...
T-cell Adult Ac...
T-cell Childhoo...
therapeutic all...
aldesleukin
peripheral bloo...
allogeneic bone...
laboratory biom...
gene expression...
immunologic tec...
flow cytometry
polymerase chai...
cytogenetic ana...
staining method
- Fred Hutchinson Cancer Center
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaNCT00053963
Blastic Phase C...
Childhood Centr...
Childhood Choro...
Childhood Chron...
Childhood Crani...
Childhood Grade...
Childhood Grade...
Childhood Grade...
Childhood High-...
Childhood Infra...
Childhood Low-g...
Childhood Spina...
Childhood Supra...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Refractory Chro...
Relapsing Chron...
Unspecified Chi...
romidepsin
- 21 YearsNational Cancer Institute (NCI)
STI571 in Treating Patients With Recurrent LeukemiaNCT00004932
Leukemia
imatinib mesyla...
- 21 YearsChildren's Oncology Group
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic MalignancyNCT00891137
Leukemia
Lymphoma
Multiple Myelom...
Plasma Cell Neo...
Myelodysplastic...
human myeloid p...
12 Years - 65 YearsCellerant Therapeutics
Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive LeukemiaNCT00244829
Leukemia
imatinib mesyla...
adjuvant therap...
- Fred Hutchinson Cancer Center
Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First RemissionNCT00305708
Congenital Ameg...
Diamond-blackfa...
Fanconi Anemia
Leukemia
Severe Congenit...
Thrombocytopeni...
anti-thymocyte ...
busulfan
fludarabine pho...
allogeneic bone...
peripheral bloo...
umbilical cord ...
radiation thera...
- 17 YearsUniversity of California, San Francisco
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerNCT00112567
Leukemia
Myelodysplastic...
fludarabine pho...
thiotepa
peripheral bloo...
radiation thera...
- 20 YearsFred Hutchinson Cancer Center
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous LeukemiaNCT00002771
Leukemia
recombinant int...
busulfan
cytarabine
hydroxyurea
idarubicin
allogeneic bone...
autologous bone...
peripheral bloo...
radiation thera...
- National Cancer Institute (NCI)
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic CancerNCT00290641
Chronic Myelopr...
Leukemia
Lymphoma
Myelodysplastic...
filgrastim
graft-versus-tu...
cyclophosphamid...
cyclosporine
fludarabine pho...
mycophenolate m...
umbilical cord ...
radiation thera...
- 45 YearsMasonic Cancer Center, University of Minnesota
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood DiseasesNCT00450983
Graft Versus Ho...
Leukemia
Myelodysplastic...
muromonab-CD3
natural killer ...
fludarabine pho...
methotrexate
thiotepa
gene expression...
flow cytometry
immunologic tec...
allogeneic hema...
in vitro-treate...
total-body irra...
- 45 YearsFred Hutchinson Cancer Center
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous LeukemiaNCT00002771
Leukemia
recombinant int...
busulfan
cytarabine
hydroxyurea
idarubicin
allogeneic bone...
autologous bone...
peripheral bloo...
radiation thera...
- National Cancer Institute (NCI)
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaNCT00045422
Leukemia
recombinant int...
imatinib mesyla...
- Memorial Sloan Kettering Cancer Center
Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic CancerNCT00126477
Leukemia
Lymphoma
Myelodysplastic...
Quality of Life
cognitive asses...
management of t...
psychosocial as...
quality-of-life...
18 Years - Fred Hutchinson Cancer Center
Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive LeukemiaNCT00244829
Leukemia
imatinib mesyla...
adjuvant therap...
- Fred Hutchinson Cancer Center
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other DiseasesNCT00450450
Childhood Acute...
Childhood Acute...
Childhood Chron...
Childhood Myelo...
Chronic Phase C...
de Novo Myelody...
Juvenile Myelom...
Previously Trea...
Recurrent Child...
Secondary Myelo...
allogeneic bone...
laboratory biom...
filgrastim
- 21 YearsChildren's Oncology Group
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous LeukemiaNCT00054431
Accelerated Pha...
Blastic Phase C...
Childhood Chron...
Chronic Myeloge...
Relapsing Chron...
imatinib mesyla...
decitabine
laboratory biom...
- National Cancer Institute (NCI)
Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency DiseaseNCT00295971
Congenital Ameg...
Leukemia
Myelodysplastic...
Severe Congenit...
anti-thymocyte ...
therapeutic all...
fludarabine pho...
thiotepa
allogeneic bone...
allogeneic hema...
in vitro-treate...
total-body irra...
1 Year - 17 YearsUniversity of California, San Francisco
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaNCT00045422
Leukemia
recombinant int...
imatinib mesyla...
- Memorial Sloan Kettering Cancer Center
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic CancerNCT00295880
Myeloproliferat...
Leukemia
Lymphoma
Myelodysplastic...
umbilical cord ...
12 Years - 45 YearsMasonic Cancer Center, University of Minnesota
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CMLNCT00416884
Leukemia
Campath
Fludarabine
Total Body Irra...
T-Cell Deplete
4 Years - 75 YearsOHSU Knight Cancer Institute
Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell TransplantNCT00052598
Accelerated Pha...
Acute Myeloid L...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Blastic Phase C...
Childhood Chron...
Childhood Myelo...
Recurrent Adult...
Recurrent Child...
Relapsing Chron...
Secondary Acute...
therapeutic all...
aldesleukin
laboratory biom...
flow cytometry
- Fred Hutchinson Cancer Center
Tipifarnib in Treating Young Patients With Refractory LeukemiaNCT00022451
Leukemia
tipifarnib
- 21 YearsNational Institutes of Health Clinical Center (CC)
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerNCT00112567
Leukemia
Myelodysplastic...
fludarabine pho...
thiotepa
peripheral bloo...
radiation thera...
- 20 YearsFred Hutchinson Cancer Center
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell TransplantNCT00526292
Leukemia
Myelodysplastic...
natural killer ...
cyclophosphamid...
fludarabine
- 120 YearsMemorial Sloan Kettering Cancer Center
Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaNCT00030394
Childhood Chron...
Chronic Myeloge...
Chronic Phase C...
imatinib mesyla...
laboratory biom...
pharmacological...
- 21 YearsNational Cancer Institute (NCI)
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaNCT00055874
Leukemia
recombinant int...
cytarabine
hydroxyurea
imatinib mesyla...
allogeneic bone...
autologous bone...
peripheral bloo...
18 Years - 120 YearsHeidelberg University
Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell TransplantNCT00920842
Cardiovascular ...
Leukemia
Long-term Effec...
Metabolic Syndr...
9 Years - 21 YearsFred Hutchinson Cancer Center
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic MalignancyNCT00891137
Leukemia
Lymphoma
Multiple Myelom...
Plasma Cell Neo...
Myelodysplastic...
human myeloid p...
12 Years - 65 YearsCellerant Therapeutics
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous LeukemiaNCT00025402
Leukemia
filgrastim
recombinant int...
busulfan
cyclophosphamid...
cytarabine
etoposide
hydroxyurea
idarubicin
allogeneic bone...
peripheral bloo...
radiation thera...
- National Cancer Institute (NCI)
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or LeukemiaNCT00053963
Blastic Phase C...
Childhood Centr...
Childhood Choro...
Childhood Chron...
Childhood Crani...
Childhood Grade...
Childhood Grade...
Childhood Grade...
Childhood High-...
Childhood Infra...
Childhood Low-g...
Childhood Spina...
Childhood Supra...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Recurrent Child...
Refractory Chro...
Relapsing Chron...
Unspecified Chi...
romidepsin
- 21 YearsNational Cancer Institute (NCI)
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical TrialNCT00890435
Brain and Centr...
Leukemia
Unspecified Adu...
Unspecified Chi...
questionnaire a...
psychosocial as...
18 Years - Children's Oncology Group
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other DiseasesNCT00450450
Childhood Acute...
Childhood Acute...
Childhood Chron...
Childhood Myelo...
Chronic Phase C...
de Novo Myelody...
Juvenile Myelom...
Previously Trea...
Recurrent Child...
Secondary Myelo...
allogeneic bone...
laboratory biom...
filgrastim
- 21 YearsChildren's Oncology Group
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic LeukemiaNCT00860574
Accelerated Pha...
Adult Acute Lym...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Adult Acute Mye...
Blastic Phase C...
Childhood Acute...
Childhood Acute...
Childhood Chron...
Childhood Myelo...
Chronic Myelomo...
de Novo Myelody...
Previously Trea...
Recurrent Adult...
Recurrent Adult...
Recurrent Child...
Recurrent Child...
Secondary Myelo...
Untreated Adult...
Untreated Child...
treosulfan
fludarabine pho...
total-body irra...
peripheral bloo...
tacrolimus
allogeneic bone...
allogeneic hema...
methotrexate
- 60 YearsFred Hutchinson Cancer Center
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib MesylateNCT00316953
Accelerated Pha...
Blastic Phase C...
Childhood Chron...
Chronic Myeloge...
Meningeal Chron...
Recurrent Child...
Relapsing Chron...
Unspecified Chi...
dasatinib
pharmacological...
laboratory biom...
1 Year - 21 YearsNational Cancer Institute (NCI)
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous LeukemiaNCT00003727
Leukemia
filgrastim
recombinant int...
sargramostim
therapeutic aut...
carmustine
cyclophosphamid...
etoposide
gemcitabine hyd...
melphalan
bone marrow abl...
in vitro-treate...
- 120 YearsUniversity of Maryland, Baltimore
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical TrialNCT00890435
Brain and Centr...
Leukemia
Unspecified Adu...
Unspecified Chi...
questionnaire a...
psychosocial as...
18 Years - Children's Oncology Group
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaNCT00045422
Leukemia
recombinant int...
imatinib mesyla...
- Memorial Sloan Kettering Cancer Center
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other DiseaseNCT00392782
Leukemia
Myelodysplastic...
anti-thymocyte ...
fludarabine pho...
thiotepa
peripheral bloo...
total-body irra...
- 60 YearsMasonic Cancer Center, University of Minnesota
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic CancerNCT00112567
Leukemia
Myelodysplastic...
fludarabine pho...
thiotepa
peripheral bloo...
radiation thera...
- 20 YearsFred Hutchinson Cancer Center
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: